What are the recommended amikacin dosing regimens for adults and children, including adjustments for renal impairment?

Amikacin Dosing Recommendations

For adults and children with normal renal function, administer amikacin 15 mg/kg/day divided as either 7.5 mg/kg every 12 hours or 5 mg/kg every 8 hours, with a maximum daily dose of 1.5 grams, and adjust dosing in renal impairment by either extending intervals (multiply serum creatinine by 9 for hours between doses) or reducing doses proportionally to creatinine clearance. 1

Standard Dosing for Normal Renal Function

Adults and Children

• Standard regimen: 15 mg/kg/day total
  • Option 1: 7.5 mg/kg every 12 hours
  • Option 2: 5 mg/kg every 8 hours
• Maximum daily dose: 1.5 grams regardless of weight
• Duration: 7-10 days (limit to short-term when feasible)
• Route: IV over 30-60 minutes or IM 1

Newborns (Special Population)

• Loading dose: 10 mg/kg initially
• Maintenance: 7.5 mg/kg every 12 hours 1
• Infusion time: 1-2 hours for infants 1

Uncomplicated UTIs

• Reduced dose option: 250 mg twice daily 1

Therapeutic Drug Monitoring Targets

Critical monitoring parameters to ensure efficacy while avoiding toxicity:

• Peak concentrations (30-90 minutes post-infusion):
  • Daily dosing: 35-45 μg/mL
  • Intermittent dosing: 65-80 μg/mL
  • Avoid exceeding 35 μg/mL 2
• Trough concentrations (just before next dose):
  • Target: <5 mg/L
  • Avoid exceeding 10 μg/mL 1

Renal Impairment Adjustments

The FDA label provides two distinct strategies for dose adjustment 1:

Strategy 1: Extended Interval Dosing (Simpler)

Use when creatinine clearance is unavailable:

• Calculate dosing interval in hours = Serum creatinine (mg/dL) × 9
• Example: If serum creatinine = 2 mg/dL, give 7.5 mg/kg every 18 hours
• Administer the normal single dose (7.5 mg/kg) at these extended intervals

Strategy 2: Reduced Dose at Fixed Intervals

Use when maintaining q12h schedule is preferred:

1. Give loading dose of 7.5 mg/kg (same as normal renal function)
2. Calculate maintenance dose every 12 hours:
   • Maintenance dose = (Patient's CrCl / Normal CrCl) × Loading dose
3. Simplified alternative: Divide normal dose by serum creatinine value

Specific Recommendations from NTM Guidelines

For mycobacterial infections, the guideline provides more aggressive intermittent dosing 2:

• Daily dosing: 10-15 mg/kg/day (adjusted by drug levels)
• Intermittent dosing: 15-25 mg/kg per dose, 2-3 times weekly
• In renal impairment: Reduce dose or increase interval (e.g., 15 mg/kg 2-3 times per week)

Critical Illness and Special Populations

Recent evidence highlights important considerations for critically ill patients:

Critically ill elderly patients (>60 years) with renal dysfunction should not have initial doses reduced even with renal impairment, as volume of distribution increases significantly (mean 0.47 L/kg) 3. The correlation between creatinine clearance and amikacin clearance is poor in this population, making standard adjustments unreliable 3.

Critically ill cancer patients demonstrate altered pharmacokinetics requiring different strategies 4:

• Mild renal dysfunction (CrCl ≥60 mL/min): Consider 20-30 mg/kg with extended intervals (q24-72h)
• Severe renal dysfunction (CrCl <60 mL/min): 7.5-20 mg/kg with extended intervals (q24-48h)

High-Dose Regimens

EUCAST recommendations suggest 25-30 mg/kg dosing for optimal pharmacodynamic targets (AUC/MIC >80) 5. However, this systematic review found:

• 59.6-81.8% of patients achieved target peaks of 60-80 mg/L
• Limited safety data on renal and ototoxicity at these doses
• Use cautiously, particularly in elderly patients 5

Safety Monitoring

Mandatory monitoring when treatment exceeds 10 days 1:

• Serum amikacin levels (peak and trough)
• Renal function (serum creatinine, creatinine clearance)
• Auditory function
• Vestibular function

Key toxicity concerns:

• Nephrotoxicity: Lower trough concentrations reduce risk, though optimal threshold unclear 6
• Ototoxicity: Approximately one-third of patients developed permanent ototoxicity with 15-week regimens; risk increases with age and cumulative dose 2
• Concomitant vancomycin significantly increases nephrotoxicity risk 6

Critical Pitfalls to Avoid

1. Do not use dialysis-based adjustments for non-dialysis patients 1
2. Do not exceed 15 mg/kg/day total dose by all routes combined 1
3. Do not rely solely on BUN for renal function assessment—use serum creatinine or creatinine clearance 1
4. Reassess therapy if no clinical response within 3-5 days—may indicate resistance or need for surgical drainage 1
5. In obesity (BMI ≥30), adjust dosing weight appropriately 5
6. Measure drug levels whenever possible rather than relying solely on calculated adjustments 1